Company profile
Zoetis Inc.
NYSE: ZTS · Healthcare · Drug Manufacturers - General
#44 of 1,422 Healthcare companies by revenue45th-percentile growth
EA Score
82B+FH 84DQ 87GM 63SS 85
v0.1 · 65/100 weight · provisional
↑ return on equity, market scale · ↓ balance-sheet leverage, revenue growth (YoY)
Methodology →Revenue TTM
$9.5B
Rev growth YoY (TTM)
+2.4%
Net income (FY)
$2.7B
Employees
14,500
as of 2026-08-05
Market cap
$31.9B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$9.5B$9.5B2025
Net income$2.7B$2.7B2025
Total assets$15.5B$15.5B2025
Liabilities$12.1B$12.1B2025
Equity$3.3B$3.3B2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Horses68%
Cattle16%
Swine5%
Poultry5%
Dogs and Cats3%
Fish3%
By geography
United States55%
International45%
The read
What is Zoetis Inc.’s revenue?
Zoetis Inc. booked $9.5B in FY2025 revenue, growing 2.3% year over year — about the middle of the pack among Healthcare companies we track, at a 28.2% net margin.
Peers · Healthcare
Bausch Health Companies Inc.82B+Intuitive Surgical, Inc.90ABiogen Inc.85ASolventum Corporation65BZimmer Biomet Holdings, Inc.80B+Agilent Technologies, Inc.85ANeighbors
Morris →Key facts
CEOKristin C. Peck
SectorHealthcare
IndustryDrug Manufacturers - General
HeadquartersParsippany, NJ
ExchangeNYSE: ZTS
Employees14,500
IPO date2013-02-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.